1. Evaluation of sequential application of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) after chemotherapy in advanced non-small cell lung cancerpatients with EGFR-TKI acquired resistance
Yanxia JI ; Zhenqiao KANG ; Yongge CHEN ; Xiaoguang ZHANG ; Jing LI
Chinese Journal of Postgraduates of Medicine 2018;41(8):731-734
Objective:
To explore the therapeutic efficacy and safety of chemotherapy sequential epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for advanced non-small cell lung cancer (NSCLC) patients with EGFR-TKI acquired resistance.
Methods:
The clinical features of 96 advanced NSCLC patients with EGFR mutation positive and EGFR-TKI acquired resistance from January 2013 to December 2016 were retrospectively reviewed. Forty-five patients who received chemotherapy sequential EGFR-TKI were enrolled in observation group, and another fifty-one who accepted chemotherapy alone were enrolled in control group. The objective response rates, disease control rates and adverse effects were compared between two groups.
Results:
Compared with that of the control group, the objective response rate of the observation group was significantly higher [24.4% (11/45) vs.11.8% (6/51),